Q2 2022 Earnings Estimate for Gossamer Bio, Inc. Issued By SVB Leerink (NASDAQ:GOSS)

Gossamer Bio, Inc. (NASDAQ:GOSSGet Rating) – Equities researchers at SVB Leerink increased their Q2 2022 EPS estimates for Gossamer Bio in a report issued on Tuesday, May 10th. SVB Leerink analyst J. Schwartz now forecasts that the company will earn ($0.64) per share for the quarter, up from their prior estimate of ($0.72). SVB Leerink also issued estimates for Gossamer Bio’s Q3 2022 earnings at ($0.61) EPS, Q4 2022 earnings at ($0.65) EPS, FY2022 earnings at ($2.66) EPS, FY2023 earnings at ($2.08) EPS and FY2024 earnings at ($1.82) EPS.

GOSS has been the topic of several other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Gossamer Bio in a research note on Monday. UBS Group assumed coverage on shares of Gossamer Bio in a research note on Wednesday, April 6th. They set a “buy” rating and a $19.00 price target for the company. Zacks Investment Research raised shares of Gossamer Bio from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a report on Monday. Barclays reduced their price objective on shares of Gossamer Bio from $18.00 to $12.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 26th. Finally, Raymond James cut their price objective on shares of Gossamer Bio from $19.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 26th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $16.42.

Gossamer Bio stock opened at $8.36 on Friday. Gossamer Bio has a fifty-two week low of $6.28 and a fifty-two week high of $14.30. The company has a debt-to-equity ratio of 1.47, a current ratio of 8.32 and a quick ratio of 8.32. The stock has a fifty day moving average of $8.57 and a two-hundred day moving average of $9.99.

Gossamer Bio (NASDAQ:GOSSGet Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.01.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Credit Suisse AG increased its position in Gossamer Bio by 2.9% in the 3rd quarter. Credit Suisse AG now owns 34,055 shares of the company’s stock worth $428,000 after purchasing an additional 964 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in Gossamer Bio by 10.1% during the first quarter. DekaBank Deutsche Girozentrale now owns 16,300 shares of the company’s stock worth $145,000 after buying an additional 1,500 shares in the last quarter. California State Teachers Retirement System raised its holdings in Gossamer Bio by 2.3% in the 4th quarter. California State Teachers Retirement System now owns 75,805 shares of the company’s stock valued at $857,000 after buying an additional 1,713 shares during the last quarter. Parametric Portfolio Associates LLC grew its position in Gossamer Bio by 6.6% in the 4th quarter. Parametric Portfolio Associates LLC now owns 35,846 shares of the company’s stock valued at $405,000 after purchasing an additional 2,233 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Gossamer Bio by 26.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,193 shares of the company’s stock worth $115,000 after acquiring an additional 2,772 shares during the last quarter. 76.90% of the stock is currently owned by institutional investors and hedge funds.

In other Gossamer Bio news, CEO Faheem Hasnain sold 19,035 shares of the stock in a transaction dated Wednesday, March 23rd. The stock was sold at an average price of $8.91, for a total transaction of $169,601.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Waage Christian sold 10,722 shares of Gossamer Bio stock in a transaction that occurred on Wednesday, March 23rd. The shares were sold at an average price of $8.91, for a total transaction of $95,533.02. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,300 shares of company stock worth $367,628. 23.30% of the stock is owned by company insiders.

Gossamer Bio Company Profile (Get Rating)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.

Featured Articles

Earnings History and Estimates for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.